<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <billNumber>2562</billNumber>
    <createDate>2017-05-20T03:11:40Z</createDate>
    <updateDate>2020-09-28T22:14:02Z</updateDate>
    <originChamber>House</originChamber>
    <billType>HR</billType>
    <introducedDate>2017-05-19</introducedDate>
    <congress>115</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 163, Number 87 (Friday, May 19, 2017)]From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. KELLY of Pennsylvania:H.R. 2562.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8 of the U.S. Constitution[Page H4390]</pre>]]></constitutionalAuthorityStatementText>
    <recordedVotes />
    <committees>
      <billCommittees>
        <item>
          <systemCode>hsif00</systemCode>
          <name>Energy and Commerce Committee</name>
          <chamber>House</chamber>
          <type>Standing</type>
          <subcommittees>
            <item>
              <systemCode>hsif14</systemCode>
              <name>Health Subcommittee</name>
              <activities>
                <item>
                  <name>Referred to</name>
                  <date>2017-05-26T15:29:07Z</date>
                </item>
              </activities>
            </item>
          </subcommittees>
          <activities>
            <item>
              <name>Referred to</name>
              <date>2017-05-19T13:04:20Z</date>
            </item>
          </activities>
        </item>
      </billCommittees>
    </committees>
    <committeeReports />
    <relatedBills>
      <item>
        <latestTitle>FDA Reauthorization Act of 2017</latestTitle>
        <congress>115</congress>
        <number>934</number>
        <type>S</type>
        <latestAction>
          <actionDate>2017-05-11</actionDate>
          <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 76.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>Making Pharmaceutical Markets More Competitive Act</latestTitle>
        <congress>115</congress>
        <number>1115</number>
        <type>S</type>
        <latestAction>
          <actionDate>2017-05-11</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2017-05-26</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <links />
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2017-05-19</actionDate>
        <links />
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2017-05-19</actionDate>
        <links />
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees />
      </item>
      <item>
        <actionDate>2017-05-19</actionDate>
        <links />
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees />
      </item>
      <actionTypeCounts>
        <placeholderTextForH>1</placeholderTextForH>
        <billReferrals>1</billReferrals>
        <introducedInTheHouse>1</introducedInTheHouse>
        <introducedInHouse>1</introducedInHouse>
      </actionTypeCounts>
      <actionByCounts>
        <houseOfRepresentatives>4</houseOfRepresentatives>
      </actionByCounts>
    </actions>
    <sponsors>
      <item>
        <bioguideId>K000376</bioguideId>
        <fullName>Rep. Kelly, Mike [R-PA-3]</fullName>
        <firstName>Mike</firstName>
        <middleName />
        <lastName>Kelly</lastName>
        <party>R</party>
        <state>PA</state>
        <identifiers>
          <lisID>2051</lisID>
          <bioguideId>K000376</bioguideId>
          <gpoId>8708</gpoId>
        </identifiers>
        <district>3</district>
        <byRequestType />
      </item>
    </sponsors>
    <cosponsors />
    <cboCostEstimates />
    <laws />
    <notes />
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Administrative remedies</name>
          </item>
          <item>
            <name>Congressional oversight</name>
          </item>
          <item>
            <name>Department of Health and Human Services</name>
          </item>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Government information and archives</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <summaries>
      <billSummaries>
        <item>
          <versionCode>00</versionCode>
          <actionDate>2017-05-19</actionDate>
          <actionDesc>Introduced in House</actionDesc>
          <lastSummaryUpdateDate>2018-02-09T15:45:37Z</lastSummaryUpdateDate>
          <text><![CDATA[<p><strong>Making Pharmaceutical Markets More Competitive Act</strong></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to&nbsp;prioritize the review of generic drug applications and supplements&nbsp;with respect to&nbsp;drugs that are in a shortage or for which there are not more than three approved drugs.</p> <p>The holder of an approved drug application must notify the FDA within 180 days of withdrawing or transferring the application or withdrawing the drug from sale.</p> <p>The FDA must maintain a list of generic drugs with three or fewer holders of approved applications. </p>]]></text>
          <updateDate>2017-05-19T04:00:00Z</updateDate>
          <name>Introduced in House</name>
        </item>
      </billSummaries>
    </summaries>
    <title>Making Pharmaceutical Markets More Competitive Act</title>
    <titles>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <parentTitleType />
        <title>To improve access to prescription drugs.</title>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <parentTitleType />
        <title>Making Pharmaceutical Markets More Competitive Act</title>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <titleType>Display Title</titleType>
        <parentTitleType />
        <title>Making Pharmaceutical Markets More Competitive Act</title>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <titleType>(Extracted from GPO) Short Titles as Introduced</titleType>
        <parentTitleType />
        <title>Making Pharmaceutical Markets More Competitive Act</title>
        <chamberCode />
        <chamberName />
      </item>
    </titles>
    <amendments />
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2017-05-19T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-115hr2562ih/xml/BILLS-115hr2562ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2017-05-26</actionDate>
      <text>Referred to the Subcommittee on Health.</text>
      <links />
    </latestAction>
    <calendarNumbers />
    <version>1.0.0</version>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

